Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives

Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives

The potent, RET-selective tyrosine kinase inhibitors (TKIs) pralsetinib and selpercatinib, are effective against the RET V804L/M gatekeeper mutants, however, adaptive mutations that cause resistance at the solvent front RET G810 residue have been found, pointing to the need for the development of th...

Full description

Bibliographic Details
Main Authors: Sara Fancelli, Enrico Caliman, Francesca Mazzoni, Marco Brugia, Francesca Castiglione, Luca Voltolini, Serena Pillozzi, Lorenzo Antonuzzo
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cancers
Subjects:
RET
NSCLC
selpercatinib
pralsetinib
solvent-front mutations
acquired resistances
Online Access:https://www.mdpi.com/2072-6694/13/5/1091

Internet

https://www.mdpi.com/2072-6694/13/5/1091

Similar Items